Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate ...
SAN DIEGO -- Half of heavily pretreated patients with platinum-refractory ovarian cancer (PROC) responded to an investigational antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN6), a small study ...
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results